
(Credit-Canva)
With the extra busy schedules people have these days, fitness tracking apps have helped many people time and track their exercise time, calories burnt and the time taken to do so. These apps also remind us to drink water, not exceed our calorie limits for the day, as well as keep exercising. However, sometimes these devices can have an adverse impact on our health. Instead of making us feel better, they can make us feel anxious or stressed. This generally happens when we become too focused on the numbers and start to worry if they aren't perfect. It's important to understand that while these trackers can be helpful, they shouldn't control our mood or make us feel bad about ourselves.
A recent study published in the Journal of the American Heart Association also found that people with heart problems who used trackers were more worried about their symptoms. With so many people using these devices, it's becoming a common problem. 20% of wearable users felt anxious and always contacted their doctors when they received an irregular rhythm notification. They also found that these devices meant increased monitoring and worrying, higher usage of AFib (atrial fibrillation) specific health care etc. These findings suggest that while wearables can help patients monitor their AFib, they may also lead to increased anxiety and health care use. More research is needed to fully understand the effects of these devices on patients, doctors, and the health care system.
We can become too focused on achieving certain goals, like a certain number of steps or a perfect sleep score. This can lead to stress and anxiety when we don't meet those goals, instead of simply using the information to support a healthy lifestyle.
If your happiness or sadness depends on the numbers your fitness tracker shows, it's a sign you might need a break. Getting a low score can make you feel like you've failed, even if you've been making healthy choices. It's normal to feel a little disappointed when you don't reach a goal, but your overall mood shouldn't be affected. If you notice that your mood changes a lot based on your tracker's data, it might be time to step away from it for a while.
If you find yourself constantly searching online to understand what your tracker's data means, it's a warning sign. Trying to interpret every number can lead to more worry and confusion. You might start to believe you have health problems that don't exist. It's important to remember that these trackers are tools, not medical professionals. Spending too much time trying to decode the data can increase your anxiety instead of helping you.
If you feel nervous or anxious when you forget your tracker or it's not working, you might be too dependent on it. You should be able to feel comfortable and relaxed without constant data. If you feel panicky when you can't see your numbers, it's a sign you need to learn to be okay without them. You should be able to trust your body's signals instead of relying only on the tracker.
If you rely only on your tracker and ignore what your body is telling you, it's a problem. Your body's signals are important. For example, you might feel well-rested, but if your tracker says your sleep quality is low, you might start to doubt yourself. It's important to listen to your body and not just the numbers. Your body knows when it's tired, hungry, or needs rest. The tracker is a tool to support your health, not replace your body’s signals.
A recent meningitis outbreak in Kent University has led to many people wandering about the MenB vaccine and whether they should be getting it. The UK Health Security Agency (UKHSA) with NHS England and the government is already coordinating a targeted vaccination programme against Meningitis B- the strain identified to cause the outbreak.
As per UKHSA, anyone in the following group has been offered preventative antibiotics which is also known as prophylaxis, is being offered the MenB vaccine. As of now, this includes:
Read: Fact Check: Did Keir Starmer Say UK ‘May Need To Go Into Lockdown’ If Meningitis Cases Keep Rising?
As of now, notes UKHSA that the risk of infection to the wider public remains low. This is because transmission of MenB requires close and prolonged contact to spread. This could only happen when people are living in the same household and with intimate contact such as kissing or sharing drinks or vapes.
The bacteria, notes UKHSA, are not as contagious as the other infections like measles and COVID 19.
Antibiotics play an important role, and almost an immediate one when it comes to responding to an outbreak. For anyone who has been in close contact with a confirmed or suspected case, preventative antibiotics are being offered to them to clear any meningococcal bacteria they may be carrying. This will reduce the risk of them becoming ill or passing the bacteria on to others.
The simple answer is a yes. UKHSA notes that if you are eligible for the MenB vaccine despite the fact that you have taken MenACWY vaccine, you should come forward and take the MenB vaccine. This is because the MenACWY vaccine does not protect you against the MenB strains, as they are both different strain. MenB has been identified as the primary cause of meningitis outbreak in Kent University.
Credit: iStock
Semaglutide is the hero ingredient in the popular drugs Ozempic (used primarily to treat Type-2 diabetes) and Wegovy (used for chronic weight management).
Semaglutide, a GLP-1 receptor agonist, has shown its prowess in lowering the risk of heart attack, stroke, or death in patients with type 2 diabetes, obesity, and heart or blood vessel disease.
With emerging preclinical evidence suggesting its potential neuroprotective and anti-inflammatory effects, an international team of researchers from the US and Taiwan focused their study on semaglutide and patients whose cancer has spread to the brain.
Cancer in the brain, also known as brain metastases, is an advanced-stage (stage IV) cancer, which is generally associated with an increased risk of morbidity and mortality in patients. Those with comorbidities like type 2 diabetes are likely to have worse outcomes.
The research, published in JAMA Network Open, showed that although the once-weekly semaglutide injections cannot directly treat cancer, they can potentially help some very ill patients live longer.
“The findings of this cohort study suggest that GLP-1 RA use was associated with a significant reduction in all-cause mortality among patients with cancer with brain metastases and type 2 diabetes, with generally consistent association across subgroups," said the team from Albert Einstein College of Medicine in New York and National Cheng Kung University Hospital in Taiwan, in the paper.
The teams analyzed medical records from 151 hospitals around the world.
They identified more than 19,000 patients with cancer, brain metastases, and type 2 diabetes. Of these, 866 had been treated with a GLP-1 drug, while over 11,000 had not.
Their final analysis included two groups of 850 patients who were compared for the effects of semaglutide and were followed for up to three years after their brain metastases were first recorded.
The patients taking semaglutide were significantly less likely to die -- about 37 percent -- during the follow-up period than those who were not.
The pattern was fairly consistent across several major cancer types, including lung cancer, breast cancer, and melanoma.
"These results build upon existing evidence that GLP-1 receptor activation modulates pathways relevant to neuro-oncologic health, including attenuation of neuroinflammation, preservation of blood–brain barrier integrity, and reduction of oxidative stress and mitochondrial dysfunction," the researchers said.
However, they also acknowledged limitations, such as the study was retrospectively conducted, which checked medical records and did not test patients in a controlled trial.
With Novo Nordisk losing its patent in many countries, the sky-high prices of Ozempic and Wegovy are likely to go down by 90 percent.
This means the drug will be available at cheaper rates to 40 per cent of the world's population.
In India, the patent ended on March 20, and since then, several companies, including Alkem Laboratories, NATCO Pharma, Eris Lifesciences, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, and Glenmark Pharmaceuticals, have launched their generic versions of semaglutide at a reduced price.
Also read: Semaglutide Becomes Cheap In India: A Gamechanger Or Health Gamble?
Who Should Avoid Semaglutide?
Semaglutide should be avoided or used with extreme caution in:
Credit: Canva
Living in more intensely developed neighborhoods may actually protect you against a stroke, a new University of Michigan study suggests.
Researchers tracked more than 25,000 adults across the US for over a decade and have now found that residents in areas with higher levels of development with more buildings, sidewalks and infrastructure, had a 2.5 percent lower risk of suffering a first-time stroke compared to residents in less developed areas.
Cathy Antonakos, research specialist senior in the U-M School of Kinesiology and first author explained: ""High-intensity development typically includes greater housing density and more commercial/retail outlets.
"These areas are more likely to feature compact land uses with access to health care, food stores, public transport and physical activity infrastructure like sidewalks, bike facilities and parks."
However, the study did not examine these environmental features, but there are some practical applications, Antonakos noted.
"For physicians, the study suggests that neighborhood-level factors may influence first-time stroke risk, in addition to individual-level factors," she said. "For planners, the findings suggest that enhancing environments with features that support cardiovascular health and physical activity may help lower the risk of first-time stroke."
Heart strokes are also one of the leading global health burdens, causing significant deaths and disability worldwide, including in India. Compared to Western countries, stroke also tends to occur at a younger age and is associated with a higher case fatality rate in the country.
One in seven stroke patients in India are young adults aged below 45 years, with hypertension leading as the major risk factor, according to a study by the Indian Council of Medical Research (ICMR).
The Global Burden of Disease Study 2021 identified hypertension, air pollution, tobacco smoking, high cholesterol, increased salt intake, and diabetes as the leading risk factors of stroke.
Incidence of stroke is increasing significantly in low- and middle-income countries (LMICs), especially in India, due to population growth, aging, and greater exposure to risk factors.
A new global study suggests that moderately drinking wine can decrease your risk dying from cardiovascular disease by 21 percent.
A group of Chinese researchers who analyzed 340,924 adults in the UK between 2006 and 2022 classified a 12-ounce beer, a 5-ounce glass of wine or a 1.5-ounce shot of liquor each contains about 14 grams of pure alcohol.
Those who consumed less than 20 grams per week, about 1.5 standard drinks, were classified as never or occasional drinkers. The low alcohol consumption group included men who drank more than 20 grams per week but no more than 20 grams per day, and women who drank between 10 grams per day and 20 grams per week.
They found those with high alcohol consumption were 24 percent more likely to die from any cause, 36 percent more likely to die from cancer and 14 percent more likely to die from heart disease.
Additionally, even low intake of spirits such as beer or cider was associated with a nine percent higher risk of dying from cardiovascular disease compared with drinking never or occasionally.
© 2024 Bennett, Coleman & Company Limited